Martinez-Majander, N <br/><br/>
Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial.  [electronic resource] 

 -  European journal of neurology  05 2020 
 - 841-848 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1468-1331 
<br/><br/><label>Standard No.: </label>10.1111/ene.14172  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aspirin--therapeutic use<br/>Brain Ischemia--complications<br/>Double-Blind Method<br/>Factor Xa Inhibitors<br/>Humans<br/>Intracranial Embolism<br/>Ischemic Stroke<br/>Neoplasms--complications<br/>Platelet Aggregation Inhibitors--adverse effects<br/>Rivaroxaban--therapeutic use<br/>Secondary Prevention